Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Discovery Of Protein That Contributes To Cancer Spread
http://www.medicalnewstoday.com/articles/132370.php
In an important finding published online in <i>Developmental Cell,</i> researchers at Albert Einstein College of Medicine of Yeshiva University, along with collaborators at Massachusetts Institute of Technology, have identified a protein likely responsible for causing breast cancer to spread.
Controversy Over Breast Cancer Screening: Oldest Old 'Hanging In The Balance?'
http://www.medicalnewstoday.com/articles/132348.php
A lack of clear-cut, scientific evidence illustrating the benefits of mammography screening in women over 80 has created a trail of controversy leading to a disturbing conclusion about cancer care in America.
Poorer Outcomes For Breast Cancer Patients With Marital Problems
http://www.medicalnewstoday.com/articles/132334.php
Breast cancer patients who have a poor relationship with their spouse may face a more difficult road to recovery than would other women, according to a new study.Researchers found that, over five years, patients in distressed marriages had higher levels of stress, less physical activity, slower recovery and more symptoms and signs of illness than did similar patients who reported good marriages.
Tools Designed To Help Guide Treatment Decisions In Breast Cancer Are Too Complex For Most Patients To Understand, UM Study Finds
http://www.medicalnewstoday.com/articles/132302.php
A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman's breast cancer returning after surgery is not very effective at explaining risk to patients.
----------------------------------------------
** CANCER / ONCOLOGY News **
New Medicine Recommendation By SMC Means Better Quality Of Life For Palliative Care Patients In Scotland
http://www.medicalnewstoday.com/articles/132376.php
The Scottish Medicines Consortium (SMC) has today recommended Relistor (methylnaltrexone bromide) for use by the NHS in Scotland. Relistor is a new treatment developed to help overcome opioid-induced constipation, a common problem for many end-of-life patients receiving palliative care.
State Policies Have Little Effect On Reducing Minors' Indoor Tanning Use
http://www.medicalnewstoday.com/articles/132363.php
A new analysis finds that state policies meant to limit minors' indoor tanning use have had little effect. Published in the January 15, 2009 issue of <i>CANCER</i>, a peer-reviewed journal of the American Cancer Society, the study indicates that additional efforts are needed to reduce indoor tanning use in youth.
Genetic Signature Predicts Outcome Of Pediatric Liver Cancer
http://www.medicalnewstoday.com/articles/132356.php
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children. The research, published by Cell Press in the December issue of the journal <i>Cancer Cell,</i> may lead to better treatments for pediatric liver cancers.
Brief Inhibition Of Cancer Target Is Effective And Less Toxic
http://www.medicalnewstoday.com/articles/132355.php
New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed. The study, published by Cell Press in the December issue of the journal <i>Cancer Cell,</i> is likely to have a major impact on the future design and implementation of targeted cancer therapies.
UK Kidney Cancer Patients Face Toxic, Out-dated Treatments With Little Hope Of Change If NICE Has Its Way
http://www.medicalnewstoday.com/articles/132343.php
Leading oncologist Professor Tim Eisen has expressed concerns that patients with advanced kidney cancer could be condemned to toxic, barely effective, 20 year-old treatments because the National Institute for Health and Clinical Excellence (NICE) is likely to rule out using all four of the new treatments it has assessed.
Race A Factor In Receiving Transplant Treatment For Bone Marrow Cancer But Does Not Affect Outcomes
http://www.medicalnewstoday.com/articles/132338.php
A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma).
Blocking Tumor Signals May Improve Anti-Tumor Response
http://www.medicalnewstoday.com/articles/132324.php
Blocking tumor driven signaling immune cells may improve a patient's immune response to cancer, according to a study conducted by Matthew Farren, in the laboratory of <a href="http://www.roswellpark.
Discovery Of An Achilles Heel In Cancer Cells
http://www.medicalnewstoday.com/articles/132312.php
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec.
New Medicine Recommendation By Scottish Medicines Consortium Means Better Quality Of Life For Palliative Care Patients In Scotland
http://www.medicalnewstoday.com/articles/132311.php
The Scottish Medicines Consortium (SMC) has today recommended Relistor (methylnaltrexone bromide) for use by the NHS in Scotland. Relistor is a new treatment developed to help overcome opioid-induced constipation, a common problem for many end-of-life patients receiving palliative care.
Colorado State Study Looks At Cancer And Poverty
http://www.medicalnewstoday.com/articles/132287.php
A report released today by the Colorado Cancer Coalition and the Colorado Comprehensive Cancer Program of the Colorado Department of Public Health and Environment recommends that efforts should be made to reduce health disparities in disadvantaged populations by ensuring that Colorado residents, regardless of income, have access to quality health education, cancer screening and cancer treatment.
Prostate Cancer Drug Reduces Testosterone Levels In As Little As Three Days Without Initial Hormone Surge
http://www.medicalnewstoday.com/articles/132282.php
More than 95 % of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of <i>BJU International.
OncoGenex Announces Significant Survival Advantage In Phase II Metastatic Prostate Cancer Trial
http://www.medicalnewstoday.com/articles/132217.php
On December 3, 2008, OncoGenex Pharmaceuticals (NASDAQ:OGXI) announced the results of its Phase 2 clinical trial comparing treatment of metastatic prostate cancer patients with its OGX-011 in combination with docetaxel and prednisone (the "OGX-011 arm") versus patients that received docetaxel and prednisone alone (the "control arm").
CHMP Recommends Approval In The European Union (EU) For New Options For Patients With Certain Primary Brain Tumors
http://www.medicalnewstoday.com/articles/132195.php
Schering-Plough Corporation (NYSE: SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of the intravenous (IV) formulation of TEMODAL(R) (temozolomide) as an alternative to the already approved oral form of temozolomide in the EU.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
Protein Levels Indicate Risk Of Death In Some Colorectal Cancer Patients
http://www.medicalnewstoday.com/articles/132350.php
A pair of proteins may help explain why people with surgically removed colorectal cancer and who are overweight, physically inactive, and follow a Western-pattern diet may have an increased risk of dying of the disease or other causes, Dana-Farber Cancer Institute scientists report in a new study.
Pilot Program Providing Colonoscopies To The Underserved - Connecticut
http://www.medicalnewstoday.com/articles/132293.php
An estimated 600 uninsured or underinsured Connecticut residents will be screened for colorectal cancer over the next year as part of a pilot program in which the University of Connecticut Health Center is a primary partner.
----------------------------------------------
** LUNG CANCER News **
Discovery Of Protein That Contributes To Cancer Spread
http://www.medicalnewstoday.com/articles/132370.php
In an important finding published online in <i>Developmental Cell,</i> researchers at Albert Einstein College of Medicine of Yeshiva University, along with collaborators at Massachusetts Institute of Technology, have identified a protein likely responsible for causing breast cancer to spread.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Preclinical Data On Kinase Inhibitor, AP24534, Demonstrating Inhibition Of All Known Variants Of The CML Target Protein BCR-ABL
http://www.medicalnewstoday.com/articles/132375.php
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of studies on its investigational, multi-targeted kinase inhibitor - AP24534 - showing complete inhibition of all known mutant variants of the target protein, Bcr-Abl, including the T315I mutant that is resistant to currently marketed therapies for chronic myeloid leukemia (CML).
Study Finds Statins Do Not Interfere With Rituximab Treatment For Lymphomas
http://www.medicalnewstoday.com/articles/132339.php
Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a Mayo Clinic study presented at the 50th Annual Meeting of the American Society of Hematology (<a href="http://www.
Data Shows Longest Ever Survival For Patients With Life-Threatening Leukaemia Treated With Breakthrough Treatment
http://www.medicalnewstoday.com/articles/132337.php
Nearly nine out of ten patients (86 percent) with a life-threatening leukaemia are still alive seven years after diagnosis when treated with Glivec (imatinib). Data from the largest clinical trial in newly diagnosed patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) demonstrate the longest overall survival observed to date in this disease area.
Why Gleevec-Type Drugs Control, But Do Not Eradicate Leukemia
http://www.medicalnewstoday.com/articles/132335.php
Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.
'Networks' Of Interactive Genes May Predict If Leukemia Is Aggressive Or Slow-Growing
http://www.medicalnewstoday.com/articles/132323.php
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.
Roswell Park Researchers Clarify Mechanisms Of Novel Therapy In Non-Hodgkin's Lymphoma Cells
http://www.medicalnewstoday.com/articles/132318.php
A significant number of patients with <a href="http://www.roswellpark.org/Site/Patient_Care/Types_of_Cancer/Hematology_Center/Lymphoma/Non_Hodgkin_Lymphoma_NHL" target="_blank" rel="nofollow">non-Hodgkin's lymphoma </a> have poor clinical outcomes because their cancer cells have become resistant to immunochemotherapy.
Second-Generation CML Drugs Show Promise As Frontline Therapy
http://www.medicalnewstoday.com/articles/132288.php
Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers at The University of Texas M.
Potential Breakthrough For T-Cell Lymphoma Patients With Drug That Mimics Folic Acid
http://www.medicalnewstoday.com/articles/132216.php
Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).
Clinical Trial Finds Lenalidomide Safe As Single Therapy For Elderly CLL Patients
http://www.medicalnewstoday.com/articles/132214.php
The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M.
Older Age Doesn't Affect Survival After Bone Marrow Transplant
http://www.medicalnewstoday.com/articles/132213.php
Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers of the Center for International Blood and Marrow Transplant Research reported at the 50th annual meeting of the American Society of Hematology.
International Clinical Study Confirms Effectiveness Of Lenalidomide For Patients With Relapsed, Aggressive Lymphoma
http://www.medicalnewstoday.com/articles/132212.php
Results of an international clinical study confirm the efficacy and safety of lenalidomide, an oral treatment, for patients with relapsed, refractory diffuse large B cell lymphoma (DLBCL). The research, led by Myron Czuczman, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), will be presented at the 2008 annual meeting of the American Society of Hematology, December 6-9, San Francisco, CA.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Prostate Cancer Drug Reduces Testosterone Levels In As Little As Three Days Without Initial Hormone Surge
http://www.medicalnewstoday.com/articles/132282.php
More than 95 % of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of <i>BJU International.
OncoGenex Announces Significant Survival Advantage In Phase II Metastatic Prostate Cancer Trial
http://www.medicalnewstoday.com/articles/132217.php
On December 3, 2008, OncoGenex Pharmaceuticals (NASDAQ:OGXI) announced the results of its Phase 2 clinical trial comparing treatment of metastatic prostate cancer patients with its OGX-011 in combination with docetaxel and prednisone (the "OGX-011 arm") versus patients that received docetaxel and prednisone alone (the "control arm").
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment